Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG:2196)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
20.18
+0.31 (1.56%)
Feb 3, 2026, 2:54 PM HKT

HKG:2196 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
38,87740,39640,91143,37738,66629,910
Other Revenue
671.23671.23488.71574.48345.58396.96
39,54941,06741,40043,95239,01130,307
Revenue Growth (YoY)
-4.96%-0.80%-5.81%12.66%28.72%6.02%
Cost of Revenue
20,76221,42621,71723,25620,29413,798
Gross Profit
18,78719,64119,68320,69618,71716,509
Selling, General & Admin
12,56312,96314,08712,99912,32811,124
Research & Development
3,7263,6444,3464,3023,8372,795
Other Operating Expenses
-58.91-47.52-44.99-88.15-57.86-108.24
Operating Expenses
16,33016,66818,49917,27516,18013,891
Operating Income
2,4572,9741,1843,4202,5372,618
Interest Expense
-1,338-1,432-1,325-963.81-822.54-880.95
Interest & Investment Income
4,0312,4783,8664,6604,8582,484
Currency Exchange Gain (Loss)
-13.36-13.3613.0362.36154.63-24.79
Other Non Operating Income (Expenses)
-84.78-41.41-57.73-31.78-31.06-81.16
EBT Excluding Unusual Items
5,0523,9653,6807,1476,6954,115
Impairment of Goodwill
----180-150-
Gain (Loss) on Sale of Investments
-384.8-115.94-488.66-2,498-110.19494.8
Gain (Loss) on Sale of Assets
431.26371.015.56125.6-15.425.71
Asset Writedown
-101.31-57.93-42.14-20.48-171.01-10.11
Other Unusual Items
-74.86-5.44109.380.25-206.1672.71
Pretax Income
4,9354,1693,2654,5746,0434,678
Income Tax Expense
885.04656.84369.5626.921,066737.86
Earnings From Continuing Operations
4,0503,5122,8953,9474,9763,940
Minority Interest in Earnings
-767.48-742.55-508.8-216.66-247.56-277.17
Net Income
3,2832,7702,3863,7314,7293,663
Preferred Dividends & Other Adjustments
--1.05---
Net Income to Common
3,2832,7702,3853,7314,7293,663
Net Income Growth
55.29%16.08%-36.04%-21.10%29.10%10.27%
Shares Outstanding (Basic)
2,6522,6702,6702,6072,5632,563
Shares Outstanding (Diluted)
2,6522,6702,6702,6072,5632,563
Shares Change (YoY)
-1.39%0.02%2.40%1.74%--
EPS (Basic)
1.241.040.891.431.851.43
EPS (Diluted)
1.241.040.891.431.851.43
EPS Growth
57.56%16.10%-37.52%-22.50%29.10%10.27%
Free Cash Flow
320.3366.79-1,922-1,671-1,035-1,857
Free Cash Flow Per Share
0.120.03-0.72-0.64-0.40-0.72
Dividend Per Share
0.3200.3200.2700.4200.5600.430
Dividend Growth
18.52%18.52%-35.71%-25.00%30.23%10.26%
Gross Margin
47.50%47.83%47.54%47.09%47.98%54.47%
Operating Margin
6.21%7.24%2.86%7.78%6.50%8.64%
Profit Margin
8.30%6.74%5.76%8.49%12.12%12.09%
Free Cash Flow Margin
0.81%0.16%-4.64%-3.80%-2.65%-6.13%
EBITDA
4,8785,5143,8835,5414,1844,083
EBITDA Margin
12.33%13.43%9.38%12.61%10.72%13.47%
D&A For EBITDA
2,4212,5402,6992,1211,6471,465
EBIT
2,4572,9741,1843,4202,5372,618
EBIT Margin
6.21%7.24%2.86%7.78%6.50%8.64%
Effective Tax Rate
17.93%15.75%11.32%13.71%17.65%15.77%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.